Email Updates

You are here

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

top

New England Journal of Medicine
August 2021

The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.